Use of antihypertensive drugs and risk of cutaneous melanoma: a nationwide nested case-control study

Abstract Background Most antihypertensives can induce dermal photosensitivity, which may increase melanoma risk. However, corroborating evidence is limited. We examined the associations between use of antihypertensives and melanoma risk. Methods A nationwide nested case-control study was conducted u...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of epidemiology 2023-06, Vol.52 (3), p.887-898
Hauptverfasser: Ghiasvand, Reza, Berge, Leon A M, Andreassen, Bettina K, Stenehjem, Jo S, Heir, Trond, Karlstad, Øystein, Juzeniene, Asta, Larsen, Inger K, Green, Adele C, Veierød, Marit B, Robsahm, Trude E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 898
container_issue 3
container_start_page 887
container_title International journal of epidemiology
container_volume 52
creator Ghiasvand, Reza
Berge, Leon A M
Andreassen, Bettina K
Stenehjem, Jo S
Heir, Trond
Karlstad, Øystein
Juzeniene, Asta
Larsen, Inger K
Green, Adele C
Veierød, Marit B
Robsahm, Trude E
description Abstract Background Most antihypertensives can induce dermal photosensitivity, which may increase melanoma risk. However, corroborating evidence is limited. We examined the associations between use of antihypertensives and melanoma risk. Methods A nationwide nested case-control study was conducted using data from the Cancer Registry of Norway, the National Registry and the Norwegian Prescription Database in 2004–15. Ten controls were randomly selected for each melanoma case, matched on sex and birth year. The study included 12 048 cases and 117 895 controls. We estimated rate ratios (RRs) with 95% confidence intervals (CIs). All analyses were adjusted for ambient ultraviolet radiation (UVR). We additionally performed active comparator analyses, and sensitivity analyses by only including new users, distinguishing between exclusive and mixed users, allowing for different latency periods, and subgroup analyses by melanoma subtype and clinical stage. Results Compared with non-use, we observed a slightly increased melanoma risk in users of diuretics (RR 1.08, CI 1.01–1.15), calcium-channel blockers (RR 1.10, CI 1.04–1.18) and drugs affecting the renin-angiotensin system (RR 1.10, CI 1.04–1.16), but not for beta blockers (RR 0.97, CI 0.92–1.03). We found no heterogeneity of associations by melanoma subtype or clinical stage and no dose-response relationship between the cumulative defined daily doses (DDDs) and melanoma. No interaction was found between cumulative DDDs and ambient UVR. Conclusions Weak associations, with lack of a dose-response relationship and lack of interactions with ambient UVR, in the DDD analysis in this nationwide study do not support a causal relationship between antihypertensives and melanoma risk.
doi_str_mv 10.1093/ije/dyac223
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10244056</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ije/dyac223</oup_id><sourcerecordid>2739067162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-3bdca60850fae1e56fe1b3cc59ed46bf0963cd187e69cb2df2f05538c86ab1733</originalsourceid><addsrcrecordid>eNp9kU1LHTEUhkNpqbe2q-5tViLI1HzPjBsRqW1B6KauQyY5o7EzyW2SUe6_N3KvYjddBXIenrwnL0KfKflKSc9P_B2cuI2xjPE3aEWFEg1XnXyLVoQT0si2pXvoQ853hFAhRP8e7XElKCesXSF3nQHHEZtQ_O1mDalAyP4esEvLTa7XDief_zwhdikmQFwynmEyIc7mFBscTPExPHgHOEAu4LA1GRobQ0lxwrksbvMRvRvNlOHT7txH15fffl_8aK5-ff95cX7VWMHb0vDBWaNIJ8logIJUI9CBWyt7cEINI-kVt452LajeDsyNbCRS8s52ygy05XwfnW2962WYwVmoGcyk18nPJm10NF7_Own-Vt_Ee00JE4JIVQ1ftgZbty4-6BCTqeNOMt13Le8rcbR7I8W_S91Yzz5bmKbt32hWIaJaqlhFj59lMecE40sSSvRTdbpWp3fVVfrgdfgX9rmrChxugbis_2t6BGhmpI4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2739067162</pqid></control><display><type>article</type><title>Use of antihypertensive drugs and risk of cutaneous melanoma: a nationwide nested case-control study</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>NORA - Norwegian Open Research Archives</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Ghiasvand, Reza ; Berge, Leon A M ; Andreassen, Bettina K ; Stenehjem, Jo S ; Heir, Trond ; Karlstad, Øystein ; Juzeniene, Asta ; Larsen, Inger K ; Green, Adele C ; Veierød, Marit B ; Robsahm, Trude E</creator><creatorcontrib>Ghiasvand, Reza ; Berge, Leon A M ; Andreassen, Bettina K ; Stenehjem, Jo S ; Heir, Trond ; Karlstad, Øystein ; Juzeniene, Asta ; Larsen, Inger K ; Green, Adele C ; Veierød, Marit B ; Robsahm, Trude E</creatorcontrib><description>Abstract Background Most antihypertensives can induce dermal photosensitivity, which may increase melanoma risk. However, corroborating evidence is limited. We examined the associations between use of antihypertensives and melanoma risk. Methods A nationwide nested case-control study was conducted using data from the Cancer Registry of Norway, the National Registry and the Norwegian Prescription Database in 2004–15. Ten controls were randomly selected for each melanoma case, matched on sex and birth year. The study included 12 048 cases and 117 895 controls. We estimated rate ratios (RRs) with 95% confidence intervals (CIs). All analyses were adjusted for ambient ultraviolet radiation (UVR). We additionally performed active comparator analyses, and sensitivity analyses by only including new users, distinguishing between exclusive and mixed users, allowing for different latency periods, and subgroup analyses by melanoma subtype and clinical stage. Results Compared with non-use, we observed a slightly increased melanoma risk in users of diuretics (RR 1.08, CI 1.01–1.15), calcium-channel blockers (RR 1.10, CI 1.04–1.18) and drugs affecting the renin-angiotensin system (RR 1.10, CI 1.04–1.16), but not for beta blockers (RR 0.97, CI 0.92–1.03). We found no heterogeneity of associations by melanoma subtype or clinical stage and no dose-response relationship between the cumulative defined daily doses (DDDs) and melanoma. No interaction was found between cumulative DDDs and ambient UVR. Conclusions Weak associations, with lack of a dose-response relationship and lack of interactions with ambient UVR, in the DDD analysis in this nationwide study do not support a causal relationship between antihypertensives and melanoma risk.</description><identifier>ISSN: 0300-5771</identifier><identifier>ISSN: 1464-3685</identifier><identifier>EISSN: 1464-3685</identifier><identifier>DOI: 10.1093/ije/dyac223</identifier><identifier>PMID: 36413027</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Antihypertensive Agents - adverse effects ; Case-Control Studies ; Humans ; Melanoma - epidemiology ; Melanoma, Cutaneous Malignant ; Miscellaneous ; Skin Neoplasms - epidemiology ; Ultraviolet Rays</subject><ispartof>International journal of epidemiology, 2023-06, Vol.52 (3), p.887-898</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of the International Epidemiological Association. 2022</rights><rights>The Author(s) 2022. Published by Oxford University Press on behalf of the International Epidemiological Association.</rights><rights>info:eu-repo/semantics/openAccess</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-3bdca60850fae1e56fe1b3cc59ed46bf0963cd187e69cb2df2f05538c86ab1733</citedby><cites>FETCH-LOGICAL-c437t-3bdca60850fae1e56fe1b3cc59ed46bf0963cd187e69cb2df2f05538c86ab1733</cites><orcidid>0000-0003-1204-787X ; 0000-0002-2083-2758 ; 0000-0002-5466-7308</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,26544,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36413027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghiasvand, Reza</creatorcontrib><creatorcontrib>Berge, Leon A M</creatorcontrib><creatorcontrib>Andreassen, Bettina K</creatorcontrib><creatorcontrib>Stenehjem, Jo S</creatorcontrib><creatorcontrib>Heir, Trond</creatorcontrib><creatorcontrib>Karlstad, Øystein</creatorcontrib><creatorcontrib>Juzeniene, Asta</creatorcontrib><creatorcontrib>Larsen, Inger K</creatorcontrib><creatorcontrib>Green, Adele C</creatorcontrib><creatorcontrib>Veierød, Marit B</creatorcontrib><creatorcontrib>Robsahm, Trude E</creatorcontrib><title>Use of antihypertensive drugs and risk of cutaneous melanoma: a nationwide nested case-control study</title><title>International journal of epidemiology</title><addtitle>Int J Epidemiol</addtitle><description>Abstract Background Most antihypertensives can induce dermal photosensitivity, which may increase melanoma risk. However, corroborating evidence is limited. We examined the associations between use of antihypertensives and melanoma risk. Methods A nationwide nested case-control study was conducted using data from the Cancer Registry of Norway, the National Registry and the Norwegian Prescription Database in 2004–15. Ten controls were randomly selected for each melanoma case, matched on sex and birth year. The study included 12 048 cases and 117 895 controls. We estimated rate ratios (RRs) with 95% confidence intervals (CIs). All analyses were adjusted for ambient ultraviolet radiation (UVR). We additionally performed active comparator analyses, and sensitivity analyses by only including new users, distinguishing between exclusive and mixed users, allowing for different latency periods, and subgroup analyses by melanoma subtype and clinical stage. Results Compared with non-use, we observed a slightly increased melanoma risk in users of diuretics (RR 1.08, CI 1.01–1.15), calcium-channel blockers (RR 1.10, CI 1.04–1.18) and drugs affecting the renin-angiotensin system (RR 1.10, CI 1.04–1.16), but not for beta blockers (RR 0.97, CI 0.92–1.03). We found no heterogeneity of associations by melanoma subtype or clinical stage and no dose-response relationship between the cumulative defined daily doses (DDDs) and melanoma. No interaction was found between cumulative DDDs and ambient UVR. Conclusions Weak associations, with lack of a dose-response relationship and lack of interactions with ambient UVR, in the DDD analysis in this nationwide study do not support a causal relationship between antihypertensives and melanoma risk.</description><subject>Antihypertensive Agents - adverse effects</subject><subject>Case-Control Studies</subject><subject>Humans</subject><subject>Melanoma - epidemiology</subject><subject>Melanoma, Cutaneous Malignant</subject><subject>Miscellaneous</subject><subject>Skin Neoplasms - epidemiology</subject><subject>Ultraviolet Rays</subject><issn>0300-5771</issn><issn>1464-3685</issn><issn>1464-3685</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><sourceid>3HK</sourceid><recordid>eNp9kU1LHTEUhkNpqbe2q-5tViLI1HzPjBsRqW1B6KauQyY5o7EzyW2SUe6_N3KvYjddBXIenrwnL0KfKflKSc9P_B2cuI2xjPE3aEWFEg1XnXyLVoQT0si2pXvoQ853hFAhRP8e7XElKCesXSF3nQHHEZtQ_O1mDalAyP4esEvLTa7XDief_zwhdikmQFwynmEyIc7mFBscTPExPHgHOEAu4LA1GRobQ0lxwrksbvMRvRvNlOHT7txH15fffl_8aK5-ff95cX7VWMHb0vDBWaNIJ8logIJUI9CBWyt7cEINI-kVt452LajeDsyNbCRS8s52ygy05XwfnW2962WYwVmoGcyk18nPJm10NF7_Own-Vt_Ee00JE4JIVQ1ftgZbty4-6BCTqeNOMt13Le8rcbR7I8W_S91Yzz5bmKbt32hWIaJaqlhFj59lMecE40sSSvRTdbpWp3fVVfrgdfgX9rmrChxugbis_2t6BGhmpI4</recordid><startdate>20230606</startdate><enddate>20230606</enddate><creator>Ghiasvand, Reza</creator><creator>Berge, Leon A M</creator><creator>Andreassen, Bettina K</creator><creator>Stenehjem, Jo S</creator><creator>Heir, Trond</creator><creator>Karlstad, Øystein</creator><creator>Juzeniene, Asta</creator><creator>Larsen, Inger K</creator><creator>Green, Adele C</creator><creator>Veierød, Marit B</creator><creator>Robsahm, Trude E</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>3HK</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1204-787X</orcidid><orcidid>https://orcid.org/0000-0002-2083-2758</orcidid><orcidid>https://orcid.org/0000-0002-5466-7308</orcidid></search><sort><creationdate>20230606</creationdate><title>Use of antihypertensive drugs and risk of cutaneous melanoma: a nationwide nested case-control study</title><author>Ghiasvand, Reza ; Berge, Leon A M ; Andreassen, Bettina K ; Stenehjem, Jo S ; Heir, Trond ; Karlstad, Øystein ; Juzeniene, Asta ; Larsen, Inger K ; Green, Adele C ; Veierød, Marit B ; Robsahm, Trude E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-3bdca60850fae1e56fe1b3cc59ed46bf0963cd187e69cb2df2f05538c86ab1733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antihypertensive Agents - adverse effects</topic><topic>Case-Control Studies</topic><topic>Humans</topic><topic>Melanoma - epidemiology</topic><topic>Melanoma, Cutaneous Malignant</topic><topic>Miscellaneous</topic><topic>Skin Neoplasms - epidemiology</topic><topic>Ultraviolet Rays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghiasvand, Reza</creatorcontrib><creatorcontrib>Berge, Leon A M</creatorcontrib><creatorcontrib>Andreassen, Bettina K</creatorcontrib><creatorcontrib>Stenehjem, Jo S</creatorcontrib><creatorcontrib>Heir, Trond</creatorcontrib><creatorcontrib>Karlstad, Øystein</creatorcontrib><creatorcontrib>Juzeniene, Asta</creatorcontrib><creatorcontrib>Larsen, Inger K</creatorcontrib><creatorcontrib>Green, Adele C</creatorcontrib><creatorcontrib>Veierød, Marit B</creatorcontrib><creatorcontrib>Robsahm, Trude E</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>NORA - Norwegian Open Research Archives</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghiasvand, Reza</au><au>Berge, Leon A M</au><au>Andreassen, Bettina K</au><au>Stenehjem, Jo S</au><au>Heir, Trond</au><au>Karlstad, Øystein</au><au>Juzeniene, Asta</au><au>Larsen, Inger K</au><au>Green, Adele C</au><au>Veierød, Marit B</au><au>Robsahm, Trude E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of antihypertensive drugs and risk of cutaneous melanoma: a nationwide nested case-control study</atitle><jtitle>International journal of epidemiology</jtitle><addtitle>Int J Epidemiol</addtitle><date>2023-06-06</date><risdate>2023</risdate><volume>52</volume><issue>3</issue><spage>887</spage><epage>898</epage><pages>887-898</pages><issn>0300-5771</issn><issn>1464-3685</issn><eissn>1464-3685</eissn><abstract>Abstract Background Most antihypertensives can induce dermal photosensitivity, which may increase melanoma risk. However, corroborating evidence is limited. We examined the associations between use of antihypertensives and melanoma risk. Methods A nationwide nested case-control study was conducted using data from the Cancer Registry of Norway, the National Registry and the Norwegian Prescription Database in 2004–15. Ten controls were randomly selected for each melanoma case, matched on sex and birth year. The study included 12 048 cases and 117 895 controls. We estimated rate ratios (RRs) with 95% confidence intervals (CIs). All analyses were adjusted for ambient ultraviolet radiation (UVR). We additionally performed active comparator analyses, and sensitivity analyses by only including new users, distinguishing between exclusive and mixed users, allowing for different latency periods, and subgroup analyses by melanoma subtype and clinical stage. Results Compared with non-use, we observed a slightly increased melanoma risk in users of diuretics (RR 1.08, CI 1.01–1.15), calcium-channel blockers (RR 1.10, CI 1.04–1.18) and drugs affecting the renin-angiotensin system (RR 1.10, CI 1.04–1.16), but not for beta blockers (RR 0.97, CI 0.92–1.03). We found no heterogeneity of associations by melanoma subtype or clinical stage and no dose-response relationship between the cumulative defined daily doses (DDDs) and melanoma. No interaction was found between cumulative DDDs and ambient UVR. Conclusions Weak associations, with lack of a dose-response relationship and lack of interactions with ambient UVR, in the DDD analysis in this nationwide study do not support a causal relationship between antihypertensives and melanoma risk.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>36413027</pmid><doi>10.1093/ije/dyac223</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-1204-787X</orcidid><orcidid>https://orcid.org/0000-0002-2083-2758</orcidid><orcidid>https://orcid.org/0000-0002-5466-7308</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0300-5771
ispartof International journal of epidemiology, 2023-06, Vol.52 (3), p.887-898
issn 0300-5771
1464-3685
1464-3685
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10244056
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; NORA - Norwegian Open Research Archives; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Antihypertensive Agents - adverse effects
Case-Control Studies
Humans
Melanoma - epidemiology
Melanoma, Cutaneous Malignant
Miscellaneous
Skin Neoplasms - epidemiology
Ultraviolet Rays
title Use of antihypertensive drugs and risk of cutaneous melanoma: a nationwide nested case-control study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T14%3A03%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20antihypertensive%20drugs%20and%20risk%20of%20cutaneous%20melanoma:%20a%20nationwide%20nested%20case-control%20study&rft.jtitle=International%20journal%20of%20epidemiology&rft.au=Ghiasvand,%20Reza&rft.date=2023-06-06&rft.volume=52&rft.issue=3&rft.spage=887&rft.epage=898&rft.pages=887-898&rft.issn=0300-5771&rft.eissn=1464-3685&rft_id=info:doi/10.1093/ije/dyac223&rft_dat=%3Cproquest_pubme%3E2739067162%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2739067162&rft_id=info:pmid/36413027&rft_oup_id=10.1093/ije/dyac223&rfr_iscdi=true